PA
SYRE icon

Perceptive Advisors’s Spyre Therapeutics SYRE Stock Holding History

Perceptive Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$191M Buy
3,783,225
+714,000
+23% +$26.9M 3.73% 7
2025
Q4 		$101M Buy
3,069,225
+1,839,780
+150% +$48.1M 1.79% 15
2025
Q3 		$20.6M Sell
1,229,445
-300,000
-20% -$4.89M 0.6% 45
2025
Q2 		$22.9M Sell
1,529,445
-783,827
-34% -$11.6M 0.85% 31
2025
Q1 		$37.3M Sell
2,313,272
-261,451
-10% -$5.44M 1.32% 22
2024
Q4 		$59.9M Sell
2,574,723
-297,824
-10% -$8.73M 1.65% 17
2024
Q3 		$84.5M Sell
2,872,547
-158,471
-5% -$4.41M 1.79% 15
2024
Q2 		$71.3M Buy
3,031,018
+474,339
+19% +$16M 1.72% 15
2024
Q1 		$97M Sell
2,556,679
-50,000
-2% -$1.45M 1.7% 16
2023
Q4 		$56.1M Buy
2,606,679
+2,525,563
+3,114% +$34.8M 1.25% 23
2023
Q3 		$994K Buy
+81,116
New +$1.07M 0.03% 87
2018
Q3 		– Sell
-1,028
Closed -$272K – 130
2018
Q2 		$272K Buy
+1,028
New +$253K 0.01% 119
2017
Q2 		– Sell
-233
Closed -$43K – 154
2017
Q1 		$43K Sell
233
-3,910
-94% -$552K ﹤0.01% 139
2016
Q4 		$451K Hold
4,143
– – 0.03% 125
2016
Q3 		$664K Sell
4,143
-93
-2% -$12.9K 0.04% 104
2016
Q2 		$515K Buy
+4,236
New +$812K 0.04% 117

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Perceptive Advisors's SYRE Position: Q1 2026 in Review

Perceptive Advisors increased its Spyre Therapeutics (SYRE) stake by 23% in Q1 2026, buying an estimated $26.9M and bringing the position to 3,783,225 shares worth $191M. The position accounts for 3.73% of the portfolio, ranked #7.

Perceptive Advisors first reported a position in SYRE in Q2 2016 and has held it in 16 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Perceptive Advisors held 3,783,225 shares of Spyre Therapeutics worth $191M as of Q1 2026.
  • Perceptive Advisors bought 714,000 Spyre Therapeutics shares in Q1 2026, an estimated $26.9M.
  • Spyre Therapeutics made up 3.73% of Perceptive Advisors's portfolio in Q1 2026, its #7 holding.
  • Perceptive Advisors first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 16 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.